Single and double faecal immunochemical test strategies are effective in risk stratification for patients with symptoms of per rectal bleeding suggestive of colorectal cancer ➡️doi.org/10.1093/bjsopen/zraf… Faecal immunochemical testing (FIT) is effective in detecting colorectal cancer (CRC), even in patients with per rectal bleeding (PRB), a symptom traditionally excluded from FIT use. Patients with PRB showed higher FIT positivity and greater sensitivity for CRC detection, particularly with a single FIT; no CRCs were missed when two FITs were both negative.The study supports using double FIT strategies in patients with PRB to safely guide investigation urgency and potentially reduce unnecessary invasive procedures. 👏👏👏Fatima Shah, Frances Gunn, Malcolm G Dunlop, Edinburgh Colorectal Group, Farhat V N Din, Adam D Gerrard #SoMe4Surgery #MedTwitter #SurgEd #Surgery @BJSAcademy @BJSurgery @young_bjs @OUPMedicine #colorectalsurgery #colorectalcancer @FightCRC

Clinical impact of double-faecal immunochemical testing following implementation into standard triage and investigation of primary care referrals in patients with lower gastrointestinal symptoms ➡️doi.org/10.1093/bjsopen/zraf… A double-faecal immunochemical testing pathway was implemented in secondary care for all patients with symptoms suspicious for colorectal cancer. There were very good return rates of tests, and the workload of colorectal investigations fell as a result of reassurance and watch and wait for double-negative tests. The use of a second test identifies colorectal cancers that would be missed with a single test. 👏👏👏Adam D Gerrard, Yasuko Maeda, Colin Noble, Frances Gunn, Lorna Porteous, Rebecca Cheesbrough, Alastair Thomson, Malcolm G Dunlop, Farhat V N Din, Edinburgh Colorectal Group #SoMe4Surgery #MedTwitter #SurgEd #Surgery @BJSAcademy @BJSurgery @young_bjs @OUPMedicine #colorectalsurgery #colorectalcancer @FightCRC

Risk factors and clinical consequences of interval cancers arising within faecal immunochemical testing-based colorectal cancer screening programme ➡️doi.org/10.1093/bjsopen/zraf… Bowel cancer screening uses an initial faecal immunochemical test (FIT) with a positivity threshold set so that the colonoscopy workload generated is manageable. For people with negative bowel screening who were diagnosed with colorectal cancer (CRC) within 2 years (interval CRC), the median wait was 13 months for diagnosis. Women, older patients, and those from greater socioeconomic backgrounds had a higher interval CRC rate. Almost half of these interval CRCs had a detectable FIT level at screening but below the threshold (10–79 µg haemoglobin per g). All-cause mortality was significantly greater for interval CRCs compared with screen-detected lesions. 👏👏👏Adam D Gerrard, Roberta Garau, Yasuko Maeda, Alastair Thomson, Evropi Theodoratou, Malcolm G Dunlop, Farhat V N Din #SoMe4Surgery #MedTwitter #SurgEd #Surgery @BJSAcademy @BJSurgery @young_bjs @OUPMedicine #colorectalsurgery #colorectalcancer @FightCRC